Baseline characteristics of the study cohort stratified by RVSD (defined as RVEF <45%)
| . | No RVSD (N = 1513) . | RVSD (N = 936) . | Total Cohort (N = 2449) . | P-value . |
|---|---|---|---|---|
| General characteristics | ||||
| ȃAge (mean ± SD, years) | 59.4 ± 13.9 | 60.5 ± 14.0 | 59.8 ± 14.0 | 0.07 |
| ȃAge > 65 years, n(%) | 622 (41.1) | 407 (43.5) | 1029 (42.0) | 0.09 |
| ȃFemale; n(%) | 418 (27.6) | 168 (17.9) | 586 (23.9) | <0.01 |
| ȃBMI (mean ± SD, Kg/m2) | 26.4 ± 4.5 | 26.8 ± 4.9 | 26.5 ± 4.6 | 0.07 |
| ȃBSA (mean ± SD, m2) | 1.88 ± 0.27 | 1.91 ± 0.24 | 1.89 ± 0.27 | 0.01 |
| ȃFamily history of CAD; n(%) | 448/1472 (30.4) | 266/823 (32.3) | 714/2295 (31.1) | 0.55 |
| ȃSmoker; n(%) | 556 (36.8) | 409 (43.7) | 965 (39.4) | <0.01 |
| ȃHypertension; n(%) | 763 (50.4) | 464 (49.6) | 1227 (50.1) | 0.68 |
| ȃHyperlipidemia; n(%) | 649/1482 (43.8) | 348/824 (42.2) | 997/2306 (43.2) | 0.24 |
| ȃDiabetes Mellitus; n(%) | 285 (18.8) | 245 (26.2) | 530 (21.6) | <0.01 |
| ȃCreatinine (mean ± SD, mg/dL) | 1.02 ± 0.34 | 1.12 ± 0.43 | 1.1 ± 0.4 | <0.01 |
| ȃLeft bundle branch block | 371 (24.5) | 242 (25.9) | 613 (25.0) | 0.44 |
| Symptom burden (NYHA class) | ||||
| ȃNYHA class I/II; n(%) | 1246 (82.4) | 654 (69.8) | 1900 (77.6) | <0.01 |
| ȃNYHA class III/IV; n(%) | 267 (17.6) | 282 (30.1) | 549 (22.4) | <0.01 |
| Aetiology of HF | ||||
| ȃICM; n(%) | 465 (30.7) | 475 (50.8) | 940 (38.4) | <0.01 |
| ȃIdiopathic/dilated CM; n(%) | 1028 (69.3) | 461 (49.2) | 1509 (61.6) | <0.01 |
| Medications | ||||
| ȃDiuretics; n(%) | 1028 (68.0) | 681 (72.7) | 1709 (69.7) | 0.02 |
| ȃStatin; n(%) | 684 (45.2) | 504 (53.8) | 1188 (48.5) | <0.01 |
| ȃAnti-platelet; n(%) | 811 (53.6) | 502 (53.6) | 1313 (53.6) | 0.99 |
| ȃAnti-coagulation; n(%) | 310 (20.5) | 213 (22.8) | 523 (21.4) | 0.20 |
| ȃACE-I/ARB; n(%) | 1230 (81.3) | 854 (91.2) | 2084 (85.1) | <0.01 |
| ȃBeta blocker; n(%) | 1250 (82.6) | 834 (89.1) | 2084 (85.1) | <0.01 |
| ȃAny antiarrhythmic agent; n(%) | 315 (20.8) | 115 (12.2) | 430 (17.6) | <0.01 |
| . | No RVSD (N = 1513) . | RVSD (N = 936) . | Total Cohort (N = 2449) . | P-value . |
|---|---|---|---|---|
| General characteristics | ||||
| ȃAge (mean ± SD, years) | 59.4 ± 13.9 | 60.5 ± 14.0 | 59.8 ± 14.0 | 0.07 |
| ȃAge > 65 years, n(%) | 622 (41.1) | 407 (43.5) | 1029 (42.0) | 0.09 |
| ȃFemale; n(%) | 418 (27.6) | 168 (17.9) | 586 (23.9) | <0.01 |
| ȃBMI (mean ± SD, Kg/m2) | 26.4 ± 4.5 | 26.8 ± 4.9 | 26.5 ± 4.6 | 0.07 |
| ȃBSA (mean ± SD, m2) | 1.88 ± 0.27 | 1.91 ± 0.24 | 1.89 ± 0.27 | 0.01 |
| ȃFamily history of CAD; n(%) | 448/1472 (30.4) | 266/823 (32.3) | 714/2295 (31.1) | 0.55 |
| ȃSmoker; n(%) | 556 (36.8) | 409 (43.7) | 965 (39.4) | <0.01 |
| ȃHypertension; n(%) | 763 (50.4) | 464 (49.6) | 1227 (50.1) | 0.68 |
| ȃHyperlipidemia; n(%) | 649/1482 (43.8) | 348/824 (42.2) | 997/2306 (43.2) | 0.24 |
| ȃDiabetes Mellitus; n(%) | 285 (18.8) | 245 (26.2) | 530 (21.6) | <0.01 |
| ȃCreatinine (mean ± SD, mg/dL) | 1.02 ± 0.34 | 1.12 ± 0.43 | 1.1 ± 0.4 | <0.01 |
| ȃLeft bundle branch block | 371 (24.5) | 242 (25.9) | 613 (25.0) | 0.44 |
| Symptom burden (NYHA class) | ||||
| ȃNYHA class I/II; n(%) | 1246 (82.4) | 654 (69.8) | 1900 (77.6) | <0.01 |
| ȃNYHA class III/IV; n(%) | 267 (17.6) | 282 (30.1) | 549 (22.4) | <0.01 |
| Aetiology of HF | ||||
| ȃICM; n(%) | 465 (30.7) | 475 (50.8) | 940 (38.4) | <0.01 |
| ȃIdiopathic/dilated CM; n(%) | 1028 (69.3) | 461 (49.2) | 1509 (61.6) | <0.01 |
| Medications | ||||
| ȃDiuretics; n(%) | 1028 (68.0) | 681 (72.7) | 1709 (69.7) | 0.02 |
| ȃStatin; n(%) | 684 (45.2) | 504 (53.8) | 1188 (48.5) | <0.01 |
| ȃAnti-platelet; n(%) | 811 (53.6) | 502 (53.6) | 1313 (53.6) | 0.99 |
| ȃAnti-coagulation; n(%) | 310 (20.5) | 213 (22.8) | 523 (21.4) | 0.20 |
| ȃACE-I/ARB; n(%) | 1230 (81.3) | 854 (91.2) | 2084 (85.1) | <0.01 |
| ȃBeta blocker; n(%) | 1250 (82.6) | 834 (89.1) | 2084 (85.1) | <0.01 |
| ȃAny antiarrhythmic agent; n(%) | 315 (20.8) | 115 (12.2) | 430 (17.6) | <0.01 |
Baseline characteristics of the study cohort stratified by RVSD (defined as RVEF <45%)
| . | No RVSD (N = 1513) . | RVSD (N = 936) . | Total Cohort (N = 2449) . | P-value . |
|---|---|---|---|---|
| General characteristics | ||||
| ȃAge (mean ± SD, years) | 59.4 ± 13.9 | 60.5 ± 14.0 | 59.8 ± 14.0 | 0.07 |
| ȃAge > 65 years, n(%) | 622 (41.1) | 407 (43.5) | 1029 (42.0) | 0.09 |
| ȃFemale; n(%) | 418 (27.6) | 168 (17.9) | 586 (23.9) | <0.01 |
| ȃBMI (mean ± SD, Kg/m2) | 26.4 ± 4.5 | 26.8 ± 4.9 | 26.5 ± 4.6 | 0.07 |
| ȃBSA (mean ± SD, m2) | 1.88 ± 0.27 | 1.91 ± 0.24 | 1.89 ± 0.27 | 0.01 |
| ȃFamily history of CAD; n(%) | 448/1472 (30.4) | 266/823 (32.3) | 714/2295 (31.1) | 0.55 |
| ȃSmoker; n(%) | 556 (36.8) | 409 (43.7) | 965 (39.4) | <0.01 |
| ȃHypertension; n(%) | 763 (50.4) | 464 (49.6) | 1227 (50.1) | 0.68 |
| ȃHyperlipidemia; n(%) | 649/1482 (43.8) | 348/824 (42.2) | 997/2306 (43.2) | 0.24 |
| ȃDiabetes Mellitus; n(%) | 285 (18.8) | 245 (26.2) | 530 (21.6) | <0.01 |
| ȃCreatinine (mean ± SD, mg/dL) | 1.02 ± 0.34 | 1.12 ± 0.43 | 1.1 ± 0.4 | <0.01 |
| ȃLeft bundle branch block | 371 (24.5) | 242 (25.9) | 613 (25.0) | 0.44 |
| Symptom burden (NYHA class) | ||||
| ȃNYHA class I/II; n(%) | 1246 (82.4) | 654 (69.8) | 1900 (77.6) | <0.01 |
| ȃNYHA class III/IV; n(%) | 267 (17.6) | 282 (30.1) | 549 (22.4) | <0.01 |
| Aetiology of HF | ||||
| ȃICM; n(%) | 465 (30.7) | 475 (50.8) | 940 (38.4) | <0.01 |
| ȃIdiopathic/dilated CM; n(%) | 1028 (69.3) | 461 (49.2) | 1509 (61.6) | <0.01 |
| Medications | ||||
| ȃDiuretics; n(%) | 1028 (68.0) | 681 (72.7) | 1709 (69.7) | 0.02 |
| ȃStatin; n(%) | 684 (45.2) | 504 (53.8) | 1188 (48.5) | <0.01 |
| ȃAnti-platelet; n(%) | 811 (53.6) | 502 (53.6) | 1313 (53.6) | 0.99 |
| ȃAnti-coagulation; n(%) | 310 (20.5) | 213 (22.8) | 523 (21.4) | 0.20 |
| ȃACE-I/ARB; n(%) | 1230 (81.3) | 854 (91.2) | 2084 (85.1) | <0.01 |
| ȃBeta blocker; n(%) | 1250 (82.6) | 834 (89.1) | 2084 (85.1) | <0.01 |
| ȃAny antiarrhythmic agent; n(%) | 315 (20.8) | 115 (12.2) | 430 (17.6) | <0.01 |
| . | No RVSD (N = 1513) . | RVSD (N = 936) . | Total Cohort (N = 2449) . | P-value . |
|---|---|---|---|---|
| General characteristics | ||||
| ȃAge (mean ± SD, years) | 59.4 ± 13.9 | 60.5 ± 14.0 | 59.8 ± 14.0 | 0.07 |
| ȃAge > 65 years, n(%) | 622 (41.1) | 407 (43.5) | 1029 (42.0) | 0.09 |
| ȃFemale; n(%) | 418 (27.6) | 168 (17.9) | 586 (23.9) | <0.01 |
| ȃBMI (mean ± SD, Kg/m2) | 26.4 ± 4.5 | 26.8 ± 4.9 | 26.5 ± 4.6 | 0.07 |
| ȃBSA (mean ± SD, m2) | 1.88 ± 0.27 | 1.91 ± 0.24 | 1.89 ± 0.27 | 0.01 |
| ȃFamily history of CAD; n(%) | 448/1472 (30.4) | 266/823 (32.3) | 714/2295 (31.1) | 0.55 |
| ȃSmoker; n(%) | 556 (36.8) | 409 (43.7) | 965 (39.4) | <0.01 |
| ȃHypertension; n(%) | 763 (50.4) | 464 (49.6) | 1227 (50.1) | 0.68 |
| ȃHyperlipidemia; n(%) | 649/1482 (43.8) | 348/824 (42.2) | 997/2306 (43.2) | 0.24 |
| ȃDiabetes Mellitus; n(%) | 285 (18.8) | 245 (26.2) | 530 (21.6) | <0.01 |
| ȃCreatinine (mean ± SD, mg/dL) | 1.02 ± 0.34 | 1.12 ± 0.43 | 1.1 ± 0.4 | <0.01 |
| ȃLeft bundle branch block | 371 (24.5) | 242 (25.9) | 613 (25.0) | 0.44 |
| Symptom burden (NYHA class) | ||||
| ȃNYHA class I/II; n(%) | 1246 (82.4) | 654 (69.8) | 1900 (77.6) | <0.01 |
| ȃNYHA class III/IV; n(%) | 267 (17.6) | 282 (30.1) | 549 (22.4) | <0.01 |
| Aetiology of HF | ||||
| ȃICM; n(%) | 465 (30.7) | 475 (50.8) | 940 (38.4) | <0.01 |
| ȃIdiopathic/dilated CM; n(%) | 1028 (69.3) | 461 (49.2) | 1509 (61.6) | <0.01 |
| Medications | ||||
| ȃDiuretics; n(%) | 1028 (68.0) | 681 (72.7) | 1709 (69.7) | 0.02 |
| ȃStatin; n(%) | 684 (45.2) | 504 (53.8) | 1188 (48.5) | <0.01 |
| ȃAnti-platelet; n(%) | 811 (53.6) | 502 (53.6) | 1313 (53.6) | 0.99 |
| ȃAnti-coagulation; n(%) | 310 (20.5) | 213 (22.8) | 523 (21.4) | 0.20 |
| ȃACE-I/ARB; n(%) | 1230 (81.3) | 854 (91.2) | 2084 (85.1) | <0.01 |
| ȃBeta blocker; n(%) | 1250 (82.6) | 834 (89.1) | 2084 (85.1) | <0.01 |
| ȃAny antiarrhythmic agent; n(%) | 315 (20.8) | 115 (12.2) | 430 (17.6) | <0.01 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
